The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study

• DOI: 10.3389/fonc.2021.783480
• Publication Date: 2021-12-20T06:55:25Z
• Authors: Fei Cao; Yi Yang; Tongguo Si; Jun Luo; Hui Zeng; Zhewei Zhang; Duiping Feng; Yi Chen; Jiaping Zheng
• Keywords: 03 medical and health sciences; 0302 clinical medicine; Oncology; comprehensive therapy; Neoplasms. Tumors. Oncology. Including cancer and carcinogens; hepatocellular carcinoma; transarterial chemoembolization; immunotherapy; targeted therapy; RC254-282; 3. Good health

ObjectiveTo assess the efficacy and safety of transarterial Chemoembolization (TACE) combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma (HCC).Patients and MethodsThe data of patients with unresectable HCC administered a combination therapy with TACE and lenvatinib plus sintilimab were retrospectively assessed. Patients received lenvatinib orally once daily 2 weeks before TACE, followed by sintilimab administration at 200 mg intravenously on day 1 of a 21-day therapeutic cycle after TACE. The primary endpoints were objective response rate (ORR) and duration of response (DOR) by the modified RECIST criteria.ResultsMedian duration of follow-up was 12.5 months (95%CI 9.1 to 14.8 months). ORR was 46.7% (28/60). Median DOR in confirmed responders was 10.0 months (95%CI 9.0-11.0 months). Median progression-free survival (PFS) was 13.3 months (95%CI 11.9-14.7 months). Median overall survival (OS) was 23.6 months (95%CI 22.2-25.0 months).ConclusionsTACE combined with lenvatinib plus sintilimab is a promising therapeutic regimen in unresectable hepatocellular carcinoma.